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Environmental tobacco smoke (ETS) contaminates indoor air in homes and workplaces. Although
the adverse effects of active cigarette smoking on the respiratory tract have been extensively
characterized, the effects of ETS exposure on adult asthma have not yet been investigated
extensively and the available data are limited. This article examines the evidence for ETS exposure
as a cause of asthma and asthma exacerbation in adults, and for ETS exposure in the workplace
specifically as contributing to these health effects. It addresses methodological barriers that limit the
available data and evaluates the adequacy of the data for risk assessment. Key words: airway
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This article addresses the relevant data on the
relationship ofenvironmental tobacco smoke
(ETS) exposure to asthma in adults. The
studies considered in this review were identi-
fied through a comprehensive literature
search strategy as well as through recent com-
prehensive summaries of the literature,
including the 1997 report of the California
Environmental Protection Agency (1) and
other reviews (2,3).
Specific questions to be considered
include a) whether there are data supporting
ETS as a cause of asthma in adults and if
there is information specifically related to
workplace exposure, and b) whether there
are data indicating that ETS exposure is
associated with exacerbations of asthma in
adults. These questions represent an appro-
priate starting point for determining if the
data are sufficient for a quantitative risk
assessment to be conducted on the effects of
workplace exposure to ETS on asthma in
adults. There is substantial literature on par-
ticulate air pollution and asthma but pri-
marily concerning children (4-6). This
literature may also prove informative as
additional studies are reported, particularly
of adults with asthma. Additionally, evi-
dence elsewhere in the literature (1,7)
strongly links childhood exposure to ETS
with asthma exacerbation in children and
provides some evidence that ETS increases
risk for the incidence ofasthma.
Before considering the two questions,
we describe the natural history ofasthma as
a disease and also briefly consider the role of
active cigarette smoking and its relationship
to asthma. The topic of asthma and ETS
has been recently reviewed in the 1997
report of the California Environmental
Protection Agency on ETS (1) and by
Coultas (8) in 1998.
Natural History of Asthma
Asthma is primarily a disease with its origins
in childhood (9). Halfofall asthma is diag-
nosed by 3 years of age and 80% by 6 years of
age (10). However, in many children, symp-
toms lessen with age, and many no longer
carry the diagnosis of asthma as they move
into the teen and young adult years (11).
Estimates suggest that 30-50% ofall asthma
with onset in childhood becomes asympto-
matic by early adulthood, and not all wheez-
ing illnesses in childhood reflect the presence
ofunderlying asthma (11). Factors associated
with persistence of disease include female
gender, degree of atopy or allergic predisposi-
tion, and severity of symptoms. Given this
background, a large percentage ofindividuals
entering early adult life have various features
of the asthmatic predisposition but may not
have evidence of active clinical disease. For
example, they may manifest skin test reactiv-
ity to common allergens at higher levels of
total serum IgE or asymptomatic increases in
nonspecific airways responsiveness.
There are some incident cases ofasthma in
adults, and the incidence ofasthma begins to
rise with age from the young adult years (9).
Occupational exposures account for some
cases, but the etiology ofasthma in adults has
received little investigation. Identifying per-
sons with onset of asthma during adulthood
may be difficult because many persons with an
intermediate phenotype-that is, displaying
some features of asthma but not carrying a
clinical diagnosis-may have had childhood
asthma, now forgotten. They may be unaware
of their earlier symptoms and illness history.
Thus, recall bias may influence the apparent
clinical expression of disease in adult life. A
variety offactors (allergen exposure, viral res-
piratory illness, air pollution, and active and
passive cigarette smoking) may result in
enough symptoms in an adult, formerly diag-
nosed with childhood asthma, to again pass
the clinical threshold for a diagnosis. Because
offaulty recollection ofprior asthma, recrude-
scence ofsymptoms in adults may be inter-
preted as incidence ofdisease. Consequently,
distinguishing onset ofasthma in adulthood
from recrudescence ofchildhood asthma may
be difficult. Whether the distinction is directly
relevant to preventing asthma in adults is
unclear. For this review, we consider persons
with asthma as potentially susceptible to ETS
exposure, whether the asthma was incident in
childhood or adulthood.
An additional methodological concern in
interpreting the evidence on active and pas-
sive smoking and asthma is introduced by a
form ofselection bias that has been referred
to as the healthy smoker effect (12). This bias
refers to the self-selection ofpersons with bet-
ter respiratory health to be active smokers
compared with those who remain non-
smokers. This form ofbias may well apply to
persons with childhood asthma. The degree
to which asthmatic individuals in childhood
have more severe symptoms and more severe
disease may influence their probability of
becoming active smokers; individuals who
have greater levels of airways responsiveness
or are very symptomatic may be less likely to
become regular cigarette smokers. The result-
ing bias or healthy smoker effect will tend to
obscure associations between active smoking
and asthma, particularly in cross-sectional
studies. This same type ofbias may extend to
cross-sectional studies of persons exposed to
ETS, who may choose to avoid exposure to
ETS, depending on their underlying state of
respiratory health.
The available evidence shows that
increased airways responsiveness does
determine susceptibility to the harmful
effects of active cigarette smoking, both in
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cross-sectional and longitudinal data, the latter
providing stronger support for this self-
selection (13). The bulk ofthe cross-sectional
data would support a relationship between
smoking and increased levels of airways
responsiveness despite the potential for selec-
tion bias in the studies (12). However, with
regard to an association ofactive smokingwith
asthma, the cross-sectional data are more
equivocal. Cross-sectional studies, which are
again subject to potential selection bias, have
yielded both positive (14) and negative results
(15-17). Longitudinal data, which are less
subject to the potential ofselection bias, are
unequivocal in supporting a role of active
smoking inasthmaoccurrence (18,19).
Evidence indicates that an association of
active smoking with asthma is biologically
plausible. Active cigarette smoke exposure is
associated with airways inflammation,
increased levels of peripheral blood neu-
trophils and eosinophils, increased levels of
airways responsiveness, airway wall remodel-
ing, increased levels oftotal IgE, and inflam-
mation of the small airways (20), all
indicators ofbiologic effects consistent with
the development of asthma and its inter-
mediate phenotypes. In addition, longitudi-
nal data, particularly those from the
landmark longitudinal study ofFletcher and
Peto (21) and the Lung Health Study (13),
clearly support asthma or airways responsive-
ness as defining susceptibility to active ciga-
rette smoking and accelerated decline oflung
function. With this background, we turn to
the two critical questions with regard to ETS
and asthma.
The Role of ETS in Causing
Asthma in Adults
Several studies have examined the role of
ETS exposure as a potential causative factor
for asthma in adults. Two prospective
cohort studies have assessed risk factors for
incident asthma. Hu and colleagues (22)
investigated risk factors for incident asthma
in a group ofyoung adults who had been
participants in a cross-sectional survey that
assessed passive smoking exposure at home.
Survey participants were asked to report on
a physician's diagnosis of asthma and on
symptoms and medications for those having
asthma. Parental smoking had been recorded
in an earlier survey of the same group, car-
ried out when the participants were in the
seventh grade. At 20-22 years of age,
parental smoking was a risk factor for having
physician-diagnosed asthma (odds ratio
[OR] = 2.9, 95% confidence interval [CI]:
1.6, 5.6) and current asthma (OR = 3.3;
95% CI: 1.7, 6.4).
In a study of 3,914 Seventh Day
Adventists, primarily nonsmokers, workplace
exposure to ETS was a risk factor for incident
asthma over a 10-year interval that began at a
mean age of 56.5 years (23). In this study,
Greer and colleagues tracked the develop-
ment ofrespiratory symptoms and diseases by
administering astandardized respiratory ques-
tionnaire at the start and end ofthe follow-up
interval. Incident asthma cases were identified
as a new report of a diagnosis and related
symptoms. In a multiple logistic regression
model, workplace exposure to ETS through
1987 (estimated using "years worked with a
smoker") was significantly associated with
10-year cumulative incidence; the estimated
increase for 10 years exposure = 1.45 (95%
CI: 1.21-1.80). In this study, exposure to
ETS was reported on the follow-up question-
naire and the possibility ofdifferential report-
ing of ETS exposure should be considered.
Persons developing asthma may have been
more likely to notice and report exposure
than those not developing asthma.
Flodin and co-workers (24) conducted a
population-based case-control study based in
the geographic region ofSouthern Sweden.
The investigators used a very strict definition
ofasthma that included age of onset greater
than age 20 years, documented evidence of
methacholine responsiveness, or an increase
of> 15% in FEV, (forced expiratory volume
in 1 sec) with a bronchodilator and respira-
tory symptoms consistent with asthma. ETS
exposure was assessed both at home and at
work through use ofa questionnaire. Only 29
ofthe 79 adult onset asthmatic cases were ex-
smokers for whom smoking had ended at
least 1 year before onset ofasthma. The data
clearly document that ever smoking, particu-
larly ex-smoking, was associated with the
development ofasthma in adults (OR = 3.3,
95% CI: 1.8-6.0). A total of 61 of the 79
asthmatic subjects were exposed to passive
smoking, 35 at work and 26 at home. The
odds ratio for exposure for passive smoking at
work in relation to an asthma diagnosis was
1.5 (95% CI: 0.8-2.5).
This is a relatively small case-control
study that may, in fact, underestimate the
effect ofactive cigarette smoking as a risk fac-
tor for asthma. Recall bias, both in terms of
timing ofdisease onset and exposure assess-
ment, is a potential problem in this study.
Given the limited statistical power, the find-
ing that the odds ratio for passive smoking is
not significant at p < 0.05 is not surprising.
Interpreting the magnitude ofeffect is also
limited by the sample size, as the odds ratios
are imprecisely estimated. With this con-
straint, the point estimate for the effect of
passive smoking is about halfthat ofactive
smoking. The relative similarity ofthe effects
ofactive and passive smoking does not seem
consistent with the relative doses oftobacco
smoke associated with the two exposures.
Although, the nonsignificant results might be
predicted from the small sample size, the
study data do suggest that workplace expo-
sure, particularly as assessed in this studywith
four different exposure categories, may affect
the riskofasthma in the adultpopulation.
The Swiss Study on Air Pollution and
Lung Diseases in Adults (SAPALDIA) (25)
also addressed ETS exposure and asthma in
adults. The SAPALDIA study is a cross-sec-
tional, multicity study conducted in
Switzerland that included 4,197 nonsmoking
adults between the ages of 18 and 60 years.
Asthma was defined in the standard manner
by the American Thoracic Society - Division
of Lung Diseases questionnaire as a self-
report ofa doctor's diagnosis. Never smokers
were persons who never smoked or smoked
less than 20 pack years in their lifetime,
whereas passive smokers were described as
individuals who were exposed to ETS for the
past 12 months. Workplace exposure was
assessed, both as the number ofsmokers to
whom the respondent was exposed and as the
number of hours per day of exposure. An
exhaled CO determination was performed to
assess exposure misclassification. Seventy per-
cent of males and 52% of females reported
ETS exposure. ETS exposure was associated
with an increased risk ofasthma as well as
wheezing apart from colds, dyspnea on exer-
tion, bronchitis episodes, and chronic bron-
chitis symptoms. The risk for asthma
increased with the number of smokers to
which the respondent was exposed and the
number ofhours per day, but no additional
risk was associated with workplace exposure
versus home exposure. Adjustment for a vari-
ety ofconfounding variables, including pas-
sive smoking exposure in childhood,
education, occupation, gender, and city did
not change the results for ETS overall. For
workplace ETS exposure, the risk was greater
for wheezing (OR = 2.05; 95% CI:
1.46-2.92), dyspnea (OR = 1.62; 95% CI:
1.29-2.03), symptoms ofchronic bronchitis
(OR = 1.66, 95% CI: 1.18-2.33), and bron-
chitis symptoms (OR = 1.67, 95% CI:
1.23-2.28) (25).
These studies have differing designs-
cross-sectional, cohort, and case-control-
but their findings provide an indication of
potential effects ofETS exposure in thework-
place on persons with asthma. Their results
may be subject to the complex biases consid-
ered above-both selection bias and both dif-
ferential and nondifferential misclassification
ofexposure. They highlight the difficulty and
challenge of accurately assessing workplace
exposure and of interpreting findings that
may be subject to selection bias that cannot
be characterized readily. In summary, at pre-
sent there are limited epidemiologic data on
the relationship ofETS exposure as a cause of
adult asthma.
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ETS Exposure as an
Exacerbating Factor for
Asthma in Adults:
Epidemiologic Evidence
Only a few observational studies have been
reported. These studies have used self-report
of exposure, which is potentially subject to
information bias. On days with greater sever-
ity of symptoms, for example, persons with
asthma may be more likely to notice exposure
to ETS in the microenvironments where they
spend time.
In a study carried out in India by Jindal
and colleagues (26), 200 persons with asthma
were evaluated, 100 never smokers with ETS
exposure and 100 never smokers without ETS
exposure. The definition of never smoker was
not clearly given in the report. Asthma was
defined as a physician's diagnosis with the
presence ofvariable airflow obstruction. The
design of this study incorporated an ETS
exposure questionnaire that assessed the hours
per day exposed to ETS for the past year along
with emergency room visits, hospitalization,
acute episodes, requirement of parenteral
drugs at home, corticosteroids, and mainte-
nance bronchodilators during the same time
period. ETS exposure was considered to be
present if exposure was greater than or equal
to 1 hr/day or at least 7 hr/week based on the
questionnaire. Outcomes included emergency
room visits, hospitalizations, exacerbations of
asthma, medication use, and absences from
work. The ETS-exposed asthmatics retrospec-
tively reported greater emergency room visits,
hospitalizations, medication use, and absence
from work when compared to the non-ETS
exposed asthmatic subjects.
This report is potentially subject to selec-
tion bias regarding the types ofclinical asth-
matics selected and also to the possibility of
recall bias in terms ofexposure assessment and
health outcomes. In addition, the exposure
assessment did not differentiate workplace and
home exposure to ETS. Consequently, these
positive findings need cautious interpretation.
In a panel study of 164 adults with
asthma in Denver, Colorado, Ostro et al.
(27) recorded symptoms, medications, and
exposures to indoor pollutants on a daily
basis. ETS exposure at home was assessed for
each day by self-report. Exposure to ETS was
associated with increased risk for a number
of symptoms and with restriction in activity.
Report of ETS exposure was associated with
increased risk for moderate or severe cough
(OR = 1.21; 95% CI: 1.01-1.46), moderate
or severe shortness of breath (OR = 1.85;
95% CI: 1.57-2.18), nocturnal asthma (OR
= 1.24; 95% CI 1.00-1.53), and restricted
activity (OR = 2.08; 95% CI: 1.63-2.64).
Workplace exposures were not assessed in
this study.
ETS Exposure as an
Exacerbating Factor
for Asthma in Adults:
Evidence from Controlled
Exposure Studies
By necessity, clinical studies-exposures of
volunteers to pollutants with intensive assess-
ment of responses-assess acute responses to
pollutants. An important feature ofthe con-
trolled clinical study is the opportunity to
examine both healthy volunteers and individ-
uals with underlying cardiopulmonary diseases
such as asthma. Subjects are typically classified
by age, gender, race, and lung function.
Asthmatics are often characterized by their
responsiveness to methacholine or histamine,
presence or absence of allergy (skin tests or
IgE levels), use of medication, severity of
symptoms, and degree ofairway obstruction
assessed by pulmonary function tests.
Typically, persons who are healthy or have
only mild asthma tend to volunteer for clinical
protocols, whereas more severely obstructed
asthmatics are usually not included.
A variety of studies (Table 1) have
reported on short-term exposures ofasthma-
tics to ETS generated by smoking machines
in environmental chambers. Of course, by
design, participants cannot be blinded to
being exposed to ETS because of its charac-
teristic odor. Brief exposure to ETS produces
symptoms such as eye and nasopharyngeal
irritation, with much less consistent responses
in lung function measures. In general, the
experimental studies show that brief exposure
to ETS produces symptoms such as eye and
nasopharyngeal irritation, with much less
consistent responses in lung function mea-
sures (Table 1). Early clinical studies focused
on changes in pulmonary mechanics resulting
from 1- to 2-hr exposures (28,29). For exam-
ple, Dahms and colleagues (29) observed a
mean decrease in FEV, and FVC (forced vital
capacity) of20% following a 1-hr ETS expo-
sure while asking participants not to take
bronchodilators in the few hours before expo-
sure. In contrast, Shephard et al. (28)
observed no change in lung function follow-
ing a 2-hr exposure but allowed volunteers to
use their asthma medications prior to expo-
sure. Other features of protocol design,
including subject's atopic status, history of
recent respiratory infections, or differences in
ETS concentration or exposure duration
could influence lung function.
In subsequent studies, the measurement
of airway reactivity after pollutant exposure
to increasing doses of a known broncho-
constricting agent such as methacholine was
introduced into protocol design. This
approach was incorporated into several
studies but also yielded inconsistent results
as studies demonstrated increased reactivity
(30-32), no change in reactivity (33,34) or
a decrease in reactivity (35). Although a few
studies showed adverse effects of exposure
on function, the majority documented no
significant effect on FEV, or measures of
airway responsiveness.
Because many patients with bronchial
asthma spontaneously report respiratory
symptoms during or immediately after expo-
sure to ETS, a relationship between ETS-
induced symptoms, airway caliber, and
airway responsiveness is plausible. Indeed,
Stankus et al. (36) investigated the effects of
a 2-hr exposure to ETS in 21 subjects with
asthma who previously claimed respiratory
symptoms from ETS exposure. In 7 of these
21 subjects, a fall in FEV, of > 20% was
found. These findings suggest that there
might be a subgroup ofsmoke-sensitive asth-
matic subjects who develop acute airway
obstruction after breathing ETS. A subse-
quent study by this group (32) partially con-
firmed the observation; 5 of 31 sensitive
subjects with asthma and none of39 smoke-
sensitive subjects without asthma reacted to
cigarette-smoke challenge with a > 20% fall
from baseline FEVI. However, a history of
symptoms induced by ETS has not been a
consistently reproducible marker of pul-
monary responsiveness to ETS. For example,
Jorres and Magnussen (33) exposed a group
of 24 asthmatics, 16 ofwhom had a history
of passive smoke-induced respiratory symp-
toms, to ETS for 1 hr. ETS-induced symp-
toms could not be predicted from the history
ofpassive smoke-related complaints. Airway
responsiveness to methacholine, as estimated
from spirometric or body plethysmographic
measurements, was not influenced by the
ETS challenge. In contrast to Stankus and
colleagues (36), Jorres and Magnussen con-
cluded that respiratory symptoms in smoke-
sensitive subjects are unlikely to be based on
airwayobstruction.
Several factors might have led to the
largely negative findings. Duration exposure
was generally brief, lasting 1 to 2 hr; expo-
sures oflonger duration or multiple, intermit-
tent exposures as occur in the workplace may
have enhanced airway responsiveness. Small
sample sizes in most clinical studies constrain
interpretation of the data. Often there was a
wide variability in responses among ETS-
exposed asthmatics (37), which may in part
reflect differences in subject characteristics
and exposure protocols: obstructed versus
nonobstructed asthmatics, smoke-sensitive
versus smoke-insensitive asthmatics, and sub-
ject requirements for medication.
Undoubtedly, factors in subject selection also
affect responsiveness in clinical studies. Not
only the selection criteria per se but the sub-
ject's environment is probably ofimportance.
For example, subjects living in highly
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sive (i.e., more tolerant) than those coming
from less polluted environments.
Identification of factors that predispose to
ETS responsiveness requires further investiga-
tion. However, it is notable that asthmatics
who responded to ETS on an initial exposure
responded on a second exposure 2 years later
(31). In addition, Menon and colleagues (31)
found that pretreatment with albuterol or
cromolyn can protect against ETS-induced
airway reactivity. Perhaps protection by
antioxidants accounts for some of the vari-
ability ofthe ETS-induced responses. Finally,
Nowak and colleagues (37) observed that the
nocturnal decrease in FEVy was more pro-
nounced after ETS than after sham; this
observation may be important for patients
with bronchial asthma, for whom one of the
Table 1. Pulmonary effects of ETS in asthmatics.
Investigator Design
Shephard etal., 14 asthmatics inhaled ETS for
1979 (28) 2 hr in closed room
Dahms etal.,
1981 (29)
Knight and Breslin,
1985(30)
Wiedemann et al.,
1986(35)
Stankus et al.,
1988 (36)
Menon et al.,
1991 (31)
Jorres and
Magnussen,
1992 (33)
Magnussen et al.,
1992 (34)
Menon et al.,
1992 (32)
Danuser et al.,
1993 (39)
Nowak et al.,
1997 (38)
Nowak et al.,
1997 (37)
10 asthmatics inhaled ETS for 1 hr
in a chamber
6 asthmatics inhaled ETS for 1 hr
in a room; bronchoconstrictor
response to histamine
9 asthmatics inhaled ETS for 1 hr
in a chamber; bronchoconstrictor
response to methacholine
21 smoke-sensitive asthmatics
inhaled ETS for 2 hr at 2 levels
in a chamber
15 atopic smoke-sensitive asth-
matics inhaled ETS for 2-6 hr in
a chamber; bronchoconstrictor
response to methacholine
24 asthmatics inhaled ETS for 1 hr
in a chamber; bronchoconstrictor
response to methacholine
18 adultand 11 childhood asth-
matics for 1 hr in a chamber;
bronchoconstrictor response to
methacholine or histamine
31 smoke-sensitive asthmatics
inhaled ETS for 2-6 hr in a
chamber; bronchoconstrictor
response to methacholine
10 individuals with airway hyper-
reactivity to methacholine and
respiratory symptoms inhaled ETS
17 asthmatics inhaled ETS for 3 hr
in a chamber in the evening;
bronchoconstrictor response to
methacholine
10 asthmatics inhaled ETS in a
chamber in the evening
features is nocturnal impairment of lung
function.
The evidence on short-term effects of
ETS on asthma is inconclusive but cannot be
ignored. Controlled studies of acute exposure
ofasthmatics to ETS have generated conflict-
ing data, yet there is evidence that individual
asthmatics and groups of asthmatics do
respond to levels ofETS that do not elicit
responses in healthy volunteers. Additionally,
these studies are limited in duration and do
not replicate a typical day's exposure.
Important dimensions ofstudydesign worthy
ofconsideration include using exposures of
longer duration, sequential exposures over
several days, and better characterization ofthe
asthmatic population. It is noteworthy that a
3-hr exposure ofmild asthmatics to ETS was
insufficient to invoke an inflammatory
Exposure
Smoking machine
Particles = 2-4 mg/m3
CO = 24 ppm
Smoking machine
COHb increased 0.4%
Smoke produced mechanically
Smoking machine
CO =40-50 ppm
Smoking machine
CO =9 ppm; 13 ppm
Particles = 0.9; 1.4 mg/m3
Nicotine = 0.2; 0.4 mg/m3
Smoking machine
Particles = 1.1 mg/m3
Nicotine = 0.2 mg/m3
Smoking machine
CO = 20 ppm
Particles = 3.1 mg/m3
Nicotine = 0.3 mg/m3
Smoking machine
CO=21 ppm
Particles = 2.7 mg/m3
Nicotine = 0.4 mg/m3
Smoking machine
Particles = 1.3 mg/m3
Nicotine = 0.2 mg/m3
2-min provocation testwith
increasing CO concentration
(0, 2, 4, 8, 16, 32 ppm)
Smoking machine
CO = 22 ppm
Particles = 3.2 mg/m3
Smoking machine
CO = 22 ppm
Particles = 3.2 mg/m3
response in nasal or bronchoalveolar lavage
fluid (38).
Conclusions
On the basis ofthe above review, it appears
that there are only scant data assessing the
role for ETS exposure in adult asthma. There
is some evidence that ETS exposure in gen-
eral, and especially ETS exposure in the
workplace, contributes to both development
and exacerbation of asthma. However,
because of a limited number ofstudies and
potential problems in their design, definitive
conclusions cannot be made at this time.
Data from volunteer studies and exposure
chamber studies are consistent with the epi-
demiologic data but do not, in and ofthem-
selves, consistently support the relationship
between ETS exposure and adult asthma.
Findings Comments
No change in lung function; few Aircontrol exposure
changes in symptoms
Decrease in FEVy and FVC of 20%
Increased symptoms; decrease in FEVy
and PC20
No change in lung function; decrease
in airway reactivity
No apparent group effect on lung
function
5/6 asthmatics known reactors 24
months previously had >20% fall in
FEV1 after 2-hr exposure; 9 nonreactors
remained nonreactive with 6-hr exposure
No significant effect on lung function
or airway responsiveness; eye and
nasopharyngeal irritation
No change in lung function orairway
responsiveness; eye and nasopharyn-
geal irritation
1/3 of smoke-sensitive group
increased reactivity 6-hr post-
exposure
Significant decrease in FEV1, FVC, and
MEF50
Nocturnal decrease in FEV greater
after ETS than sham; no effect on
airway responsiveness
No effect on lung function or cells in
BAL or nasal lavage
Nochange in lung function
ofcontrol subjects; no
sham exposure
Air control exposure
No control exposure;
significance ofdecrease
in airwayreactivity unclear
7/21 subjects experienced
>20% fall in FEV1; no
control exposure
Pretreatmentwith medi-
cation decreased airway
reactivity to ETS
Cross-over with air; smoke-
sensitive asthmatics not
more responsive
Cross-over with air
Heterogeneous response
and duration of response;
no control exposure
Decrease mostpronounced
afterthe lowest dose of
2 ppm
Wide interindividual
variability; cross-over
with air
Cross-overwith air
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Abbreviations: BAL, bronchoalveolar lavage; MEF50, maximal expiratory flow at 50% ofvital capacity; PC20, provocative concentration of histamine causing a 20% decrease in FEV1.
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Thus, ETS exposure has not yet been con-
firmed as a hazard for adults with asthma.
Given the importance ofthis issue, there is a
strong rationale for additional epidemiologic
studies ofETS in the indoor environment.
Clinical studies have the potential to be infor-
mative about the effects ofETS but require
careful attention to protocol design and they
cannot be blinded as to the exposure.
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